MedPath

Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol

Phase 4
Completed
Conditions
Metabolic Syndrome
Hypertension
Interventions
Registration Number
NCT01939509
Lead Sponsor
Hospital Italiano de Buenos Aires
Brief Summary

At hemodynamic level, the greater affinity of bisoprolol by the beta 1 receptor in theory could improve the peripheral arterial perfusion and could have a greater antihypertensive effect. At the same time, this could carry objectifiable improvements in the vascular tree, such as the level of arterial stiffness.

This study attempts to mark the hemodynamic differences in the same individual with hypertension and metabolic syndrome who will be exposed to both drugs at different moments. Parameters will be objectified with impedance cardiography, pulse wave velocity and central blood pressure assessment before and after taking each one of the drugs. The results will be compared to the baseline data and between themselves.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Hypertension
  • Metabolic syndrome
Read More
Exclusion Criteria
  • Severe hypertension >180/110
  • Secondary hypertension
  • Contraindication for betablockers
  • Prior treatment with betablockers (up to one month before inclusion)
  • History of neoplastic disease
  • Patients that do not sign informed consent
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Atenolol-BisoprololBisoprolol-
Atenolol-BisoprololAtenolol-
Primary Outcome Measures
NameTimeMethod
central blood pressuretwo months
Secondary Outcome Measures
NameTimeMethod
peripheral resistancetwo months
cardiac indextwo months
pulse wave velocitytwo months

Trial Locations

Locations (1)

Hospital Italiano de Buenos Aires

🇦🇷

Buenos Aires, Argentina

© Copyright 2025. All Rights Reserved by MedPath